Diversified Consumer Services
Company Overview of The University of Texas M. D. Anderson Cancer Center
The University of Texas M. D. Anderson Cancer Center is an educational institution that offers undergraduate and research programs to physicians, biomedical scientists, and other health-care professionals. The departments include behavioral medicine, biochemistry and molecular biology, cancer biology program, cancer genomics core laboratory, molecular and cellular oncology, molecular genetics, molecular hematology and therapy, molecular therapeutics, and molecular pathology. The University of Texas M. D. Anderson Cancer Center was founded in 1941 as Texas State Cancer Hospital and the Division of Cancer Research and changed its name to M. D. Anderson Hospital for Cancer Research of The Unive...
1515 Holcombe Boulevard
Houston, TX 77030
Founded in 1989
Key Executives for The University of Texas M. D. Anderson Cancer Center
Executive Vice President and Physician-In-Chief
Chairman of Department of Health Disparities Research
Vice President and Head of the Division of Pharmacy
Compensation as of Fiscal Year 2014.
The University of Texas M. D. Anderson Cancer Center Key Developments
Critical Outcome Technologies Inc. Signs Letter of Intent with the University of Texas MD Anderson Cancer Center for the Phase 1 Clinical Development of COTI-2 in Gynecological Cancers
Sep 8 14
Critical Outcome Technologies Inc. announced that it has signed a letter of intent with The University of Texas MD Anderson Cancer Center for the Phase 1 clinical development of the company's lead cancer drug candidate, COTI-2, in gynecological cancers. COTI-2 is selectively active in vivo and in vitro models with abnormal TP53. This is very exciting as TP53 is one of the "big three" of critically important genes that are not directly targetable. Further, TP53 is almost universally abnormal in high-grade serous ovarian cancer, the most common and most aggressive ovarian cancer. Thus the opportunity to test COTI-2 in ovarian cancer is both timely and exciting. The collaboration will result in COTI-2 one day becoming a breakthrough therapy not only for ovarian cancer patients, but for many patients with other common cancers. Under the terms of the proposed agreement, the Company and MD Anderson will work together to design and conduct a first in humans (Phase 1) study with oral COTI-2 in up to 40 women with advanced gynecological cancers who have failed conventional therapy. For the purposes of the study, the term "gynecological" cancers refers to cancers of the ovary, endometrium, and cervix. The parties have negotiated a cost structure for the clinical trial that is very favorable to the company. COTI's contribution is estimated at approximately USD 1.25 million with the remainder of the costs provided by MD Anderson as in kind monitoring, testing, and pharmacy capabilities. The parties anticipate that patient recruitment for the Phase 1 clinical trial will begin in early 2015.
MD Anderson Cancer Center Opens the Diagnostic Imaging Center - West Houston Near Interstate 10 and Texas 6
Sep 4 14
MD Anderson Cancer Center on Sept. 2 officially opened the Diagnostic Imaging Center - West Houston near Interstate 10 and Texas 6. The new imaging center offers a variety of imaging and laboratory services to patients with cancer or those being screened for it, regardless of whether they are MD Anderson patients. MD Anderson spent $30 million on the new imaging center, including technology and renovations to the 35,000-square-foot space it occupies the ground floor of a mid-rise office building in the Energy Corridor. It includes a women's imaging center with a separate entrance.
The University of Texas M. D. Anderson Cancer Center Presents at BIO International Convention, Jun-24-2014 10:00 AM
Apr 23 14
The University of Texas M. D. Anderson Cancer Center Presents at BIO International Convention, Jun-24-2014 10:00 AM. Venue: San Diego Convention Center, San Diego, California, United States. Speakers: Ronald A. DePinho, President.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|